• 1. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 2. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 3. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzyl alkyl sulfoxides
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzyl sulfoxides Benzyl alkyl sulfoxides

Professional Introduction to Compound with CAS No. 956753-99-4 and Product Name: 2-[(4-tert-butylphenyl)methanesulfinyl]-N-(2,4-dichlorophenyl)acetamide

The compound in question, identified by the CAS number 956753-99-4, is a specialized chemical entity with the product name 2-[(4-tert-butylphenyl)methanesulfinyl]-N-(2,4-dichlorophenyl)acetamide. This compound belongs to a class of molecules that have garnered significant attention in the field of pharmaceutical chemistry due to its unique structural and functional properties. The presence of both a methylsulfinyl group and a chlorinated phenyl moiety suggests potential applications in drug design, particularly in the development of bioactive molecules that interact with biological targets.

Recent advancements in medicinal chemistry have highlighted the importance of sulfonamide derivatives in the creation of novel therapeutic agents. The 2-[(4-tert-butylphenyl)methanesulfinyl] moiety in this compound introduces a bulky, lipophilic group that can influence both the solubility and binding affinity of the molecule. This feature is particularly valuable in designing compounds that require optimal pharmacokinetic profiles, ensuring efficient absorption, distribution, metabolism, and excretion (ADME) properties. The N-(2,4-dichlorophenyl)acetamide portion contributes to the overall electronic distribution of the molecule, potentially modulating its interaction with biological receptors.

One of the most compelling aspects of this compound is its potential as a scaffold for further derivatization. The combination of a tert-butylphenyl ring and a dichlorophenyl group creates a diverse chemical space that can be explored through structural modifications. Such modifications can fine-tune the pharmacological properties of the compound, making it an attractive candidate for preclinical and clinical studies. The use of chlorine atoms at specific positions on the phenyl ring is particularly noteworthy, as these atoms can enhance binding interactions by increasing electronic density and hydrophobicity.

In the context of current research, this compound aligns with ongoing efforts to develop small-molecule inhibitors targeting various disease pathways. For instance, studies have shown that sulfonamide derivatives can serve as potent inhibitors of enzymes involved in cancer metabolism. The methylsulfinyl group may play a crucial role in modulating enzyme activity by interacting with key residues in the active site. Additionally, the presence of a butyl group can prevent unwanted side reactions by sterically hindering non-specific interactions.

The dichlorophenyl moiety has also been extensively studied for its potential role in enhancing drug-like properties. Chlorine atoms are known to improve metabolic stability and binding affinity by participating in hydrophobic interactions and dipole-dipole forces. This makes the compound an intriguing candidate for further exploration in areas such as oncology and anti-inflammatory therapy. Researchers are particularly interested in how these structural features contribute to selective targeting without affecting off-target effects.

From a synthetic chemistry perspective, the preparation of this compound involves sophisticated methodologies that highlight its complexity and novelty. The synthesis likely requires multi-step reactions involving protection-deprotection strategies to ensure regioselectivity. Advanced techniques such as palladium-catalyzed cross-coupling reactions may be employed to construct the aromatic core effectively. The introduction of both sulfinyl and amide functionalities demands precision to avoid unwanted byproducts, underscoring the synthetic challenge but also emphasizing its scientific significance.

Recent publications have begun to explore similar sulfonamide derivatives for their therapeutic potential. For example, researchers have demonstrated that compounds containing analogous structures exhibit promising activity against certain kinases and proteases overexpressed in cancer cells. The tert-butyl substituent appears to enhance binding stability by occupying space around critical residues in protein targets, thereby improving drug efficacy. This aligns with broader trends in drug discovery where optimizing molecular geometry is key to achieving high potency.

The dichlorophenyl group's role extends beyond mere structural modification; it also influences physicochemical properties such as logP (partition coefficient), which is critical for determining oral bioavailability. By fine-tuning these parameters, chemists can design molecules that exhibit optimal pharmacokinetic profiles while maintaining strong target engagement. Such considerations are essential for advancing candidates from preclinical stages to clinical trials where efficacy and safety must be rigorously evaluated.

In conclusion, the compound identified by CAS No. 956753-99-4 represents a significant advancement in pharmaceutical chemistry due to its unique structural features and potential therapeutic applications. The interplay between its methylsulfinyl, tert-butylphenyl, and 2,4-dichlorophenyl moieties creates a versatile scaffold for drug development. Ongoing research continues to uncover new ways this molecule can be leveraged to address unmet medical needs through innovative chemical synthesis and biological evaluation.

• 400089-22-7(2-{[4-(tert-butyl)benzyl]sulfanyl}-N-(2,4-dichlorophenyl)acetamide)
• 116883-87-5(Acetamide, N-(4-amino-3,5-dichlorophenyl)-2-(ethylsulfinyl)-)
• 339107-21-0(2-[(2-CHLOROBENZYL)SULFINYL]-N-(2-CHLOROPHENYL)ACETAMIDE)
• 339107-36-7(2-[(2-CHLOROBENZYL)SULFONYL]-N-(2-CHLOROPHENYL)ACETAMIDE)
• 701227-74-9(2-(benzylsulfonyl)-N-(2,5-dichlorophenyl)acetamide)
• 723249-65-8(2-(benzylsulfonyl)-N-(2-chlorophenyl)acetamide)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)